Variables | HR | 95% CI | P value |
---|---|---|---|
Demographic data at PLEX | |||
Age | 1.007 | 0.952, 1.064 | 0.820 |
Male gender | 1.330 | 0.186, 9.528 | 0.777 |
AAV variants | 0.016 | 0.000, 60.511 | 0.327 |
ANCA within 4 weeks before PLEX | |||
MPO-ANCA | 5.710 | 0.556, 58.595 | 0.143 |
PR3-ANCA | 0.027 | 0.000, 231.881 | 0.434 |
ANCA negativity | 0.676 | 0.069, 6.581 | 0.736 |
AAV related indices at PLEX | |||
BVAS | 0.940 | 0.800, 1.104 | 0.450 |
FFS | 1.247 | 0.423, 3.678 | 0.689 |
Clinical manifestations at PLEX | |||
General | N/A | ||
Cutaneous | 0.041 | 0.000, 5,961,414.0 | 0.739 |
Mucous membrane/Eyes | N/A | ||
ENT | 0.024 | 0.000, 119.450 | 0.391 |
Pulmonary | 1.008 | 0.103, 9.837 | 0.995 |
Cardiovascular | 0.491 | 0.050, 4.786 | 0.540 |
Abdominal | N/A | ||
Renal | 0.649 | 0.067, 6.322 | 0.710 |
Nervous systemic | 0.993 | 0.102, 9.69. | 0.995 |
Reason for PLEX | |||
DAH vs. RPGN | 1.544 | 0.139, 17.193 | 0.724 |
Administered immunosuppressant drugs during follow-up | |||
CYC | 1.893 | 0.194, 18.490 | 0.583 |
RTX | 0.209 | 0.022, 2.024 | 0.177 |
AZA | 7.483 | 0.467, 119.824 | 0.155 |
MMF | 0.038 | 0.000, 5830.207 | 0.592 |
TAC | N/A | ||
None | 1.541 | 0.158, 15.021 | 0.710 |